India’s Claris, Spanish API Maker Get FDA Closeout Letters Resolving cGMP Issues
Significant deviations from good manufacturing practices (GMP) at India’s Claris Lifesciences and Spain’s Moehs Iberica S.L. appear to be resolved as both companies received closeout letters from the FDA this week.
This article is viewable by subscribers only. To view this article, please select an option below.